In Brief: U.S. Surgical Corp.
This article was originally published in The Gray Sheet
Executive Summary
U.S. Surgical Corp.: Minimally invasive surgical products firm enters agreement with Tenet HealthSystem to establish a patient registry database for monitoring clinical outcomes of gastroesophageal reflux disease patients treated by laparoscopic nissen fundoplication. To perform the procedure, a surgeon inserts endoscopic instruments through four to six puncture holes, then "manipulates the upper portion of the stomach and wraps it around the lower esophageal sphincter, forming a better functioning valve," according to USSC. More than 500 patients have undergone the procedure at nine Tenet-affiliated hospitals, the firms say...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.